Webinar: Affinity Duchenne™ and Affinity Beyond™: Updates on Investigational RGX-202 from REGENXBIO
Ғылым және технология
During this PPMD community webinar, REGENXBIO provides updates on AFFINITY DUCHENNE™, their investigational gene therapy for Duchenne muscular dystrophy and AFFINITY BEYOND™, an AAV8 antibody assessment study.
Пікірлер: 1
Well, so far so good. Let's see how these kids will develop in the coming years and especially howmuch additional benefit 2 x 10^14 dose will get the second groups and what the side-effect profiel will be.